Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FA consolidation regimens in low- and intermediate-risk acute myeloid leukemia
ChiCTR-TRC-11001475Phase 4Completed
- Sponsor
- Chinese Anti-Cancer Association
- Start
- May 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fludarabine and cytarabine in acute myeloid leukemia (AML) (3 arms), sponsored by Chinese Anti-Cancer Association. Primary endpoint: Continuous complete remission rate. Started May 2010; status: completed.
02
Drugs
fludarabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-TRC-11001475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001475.